Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-101 |
Synonyms | |
Therapy Description |
ABBV-101 is a selective BTK degrader, with activity against mutant BTK, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 605). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-101 | ABBV 101|ABBV101 | BTK inhibitor 37 | ABBV-101 is a selective BTK degrader, with activity against mutant BTK, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 605). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |